Healthcare and Pharmaceuticals
Global PEGylated Protein Therapeutics Market was valued at USD XX billion in the year 2017. Global PEGylated Protein Therapeutics market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023.
In the Global PEGylated Protein Therapeutics Market, by region Asia Pacific region holds the highest market share in 2017 and is also market is considered as the fastest growing market in the forecasted period owing to their market demands. At a country level, China and India in Asia-Pacific are projected to grow strongly in the coming years owing to the high population base.
A strong presence of pipeline drugs
Changing government regulations and norms.
Untapped emerging economies
Expected Launch of generic drugs
The global PEGylated protein therapeutics market is segmented based on product type, application, sales channel, and region. Based on product type, the market is segmented as colony stimulating factor, interferon, erythropoietin (EPO), recombinant factor VIII, monoclonal antibody, enzyme, and others.
Based on application, the market is categorized as cancer, autoimmune disease, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorder, and others. According to the sales channel, the market is divided into hospital pharmacy, the online provider, and retail pharmacy.
Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A. are some of the key players in the Global PEGylated Protein Therapeutics market.
Key Benefits for Stakeholders
PEGylated Protein Therapeutics Manufacturers
Raw material suppliers
Research and Consulting Organization
Healthcare and pharmaceutical companies
Investment research firms
By Product Type
Colony Stimulating Factor
Recombinant Factor VIII
By Sales Channel
Key Market Players
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Horizon Pharma plc.
Leadiant Biosciences S.p.A.
Merck & Co., Inc. (Schering-Plough Corporation)
Shire plc (Baxalta)
(A brief overview of 10 companies is also provided)
Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –
Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.
1.1 Market Vision
1.1.1 Market Definition
1.1.2 Market Scope
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
18.104.22.168. Key Data from Secondary Research
2.1.2. Primary Research
22.214.171.124. Key Data from Primary Research
126.96.36.199. Breakdowns of Primary Interviews
2.2. Market Size Estimation
2.2.1. Bottom-Up Approach
2.2.2. Top-Down Approach
2.2.3. Annual Revenue Process
2.3. Data Triangulation
2.4. Research Assumptions
3. Executive Summary
4. Market Overview
4.7. Supply Chain/Value Chain Analysis
4.8. Patent & Standards
5. Industry Trends
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Buyers
5.2.4. Bargaining Power of Suppliers
5.2.5. Intensity of Competitive Rivalry
6. PEGylated Protein Therapeutics Market, By Product Type
6.1 Colony Stimulating Factor
6.3 Erythropoietin (EPO)
6.4 Recombinant Factor VIII
6.5 Monoclonal Antibody
7. PEGylated Protein Therapeutics Market, By Application
7.2 Autoimmune Disease
7.4 Multiple Sclerosis
7.6 Gastrointestinal Disorder
8. PEGylated Protein Therapeutics Market, By Sales Channel
8.1 Hospital Pharmacy
8.2 Online Provider
8.3 Retail Pharmacy
9. Geographical Analysis
9.2. North America
9.4. Asia Pacific
9.4.1. South Korea
9.5.1. Latin America
9.5.2. Middle East and Africa
10. Company Profiles
(Business Overview, Financial Overview, Product write Up, Recent Developments)
10.1 Amgen Inc.
10.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
10.3 AstraZeneca PLC
10.4 Horizon Pharma plc.
10.5 Biogen Inc.
10.6 Leadiant Biosciences S.p.A.
10.7 Pfizer Inc.
10.8 Merck & Co., Inc. (Schering-Plough Corporation)
10.9. UCB S.A.
10.10 Shire plc (Baxalta)
(A brief overview of 10 companies is also provided.)
11. Competitive Analysis
11.2. Market Positioning of Key Players
11.3 Competitive Strategies Adopted by Leading Players
11.3.1. Investments & Expansions
11.3.2. New Product Launches
11.3.3. Mergers & Acquisitions
11.3.4. Agreements, Joint Ventures, and Partnerships
12.2. Available Customizations
12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)
* The list of tables and figures will be provided in the sample report.
No Content Available.